Scholar Rock Target of Unusually Large Options Trading (NASDAQ:SRRK)

Scholar Rock Holding Co. (NASDAQ:SRRK) saw some unusual options trading on Wednesday. Traders purchased 4,296 put options on the stock. This is an increase of approximately 1,387% compared to the typical volume of 289 put options.

Scholar Rock Trading Up 0.5 %

Shares of SRRK stock opened at $8.65 on Friday. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.36. The firm has a market cap of $692.26 million, a P/E ratio of -4.14 and a beta of 0.82. The business has a 50-day moving average price of $8.90 and a two-hundred day moving average price of $11.05. Scholar Rock has a 12-month low of $6.22 and a 12-month high of $21.17.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Thursday, August 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.01. During the same period in the previous year, the business posted ($0.47) earnings per share. Equities analysts anticipate that Scholar Rock will post -2.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SRRK has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Scholar Rock in a research note on Tuesday, June 25th. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Scholar Rock in a report on Thursday, August 8th. Finally, BMO Capital Markets raised their target price on shares of Scholar Rock from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $26.43.

Institutional Investors Weigh In On Scholar Rock

Institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its stake in Scholar Rock by 30.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 394,138 shares of the company’s stock worth $7,410,000 after purchasing an additional 91,754 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Scholar Rock by 95.5% in the 1st quarter. Jane Street Group LLC now owns 244,318 shares of the company’s stock valued at $4,339,000 after acquiring an additional 119,363 shares during the last quarter. Rafferty Asset Management LLC purchased a new stake in Scholar Rock during the 4th quarter valued at about $2,025,000. Kennedy Capital Management LLC bought a new position in Scholar Rock during the 1st quarter worth approximately $4,900,000. Finally, Vanguard Group Inc. increased its stake in Scholar Rock by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 2,969,534 shares of the company’s stock worth $52,739,000 after purchasing an additional 114,550 shares during the period. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.